Cancer thrives by hijacking the body's own basic survival systems, making it hard to attack tumors without collateral damage ...

Scientists at the Ruđer Bošković Institute (RBI) in Zagreb, Croatia, have discovered that the protein CENP-E, long believed ...

Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy ...

J&J will now explore Rybrevant's efficacy and safety in a Phase III trial in first-line, EGFR-driven HNSCC and colorectal ...

During a live event, Nizar M. Tannir, MD and participants discussed their takeaways from trial data on recurrent RCC ...

Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. | Merck has just ...

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic ...

Patients in cohort 9 received enfortumab vedotin at 1.25 mg/kg intravenously on days 1 and 8 plus pembrolizumab at 200 mg intravenously on day 1 of each 21-day cycle. Treatment was administered until ...

The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October 17 th and 21 st was host to the Poster presentation session. Dr. J. Connor ...

Following a Joe Rogan, Mel Gibson podcast, Florida wants to study whether ivermectin could work against cancer. There is not yet evidence it would.